Look up one drug

Exceptional Access criteria on record are for Brand(s): Doloral 1, Doloral 5 (TEMPORARY BENEFIT); DOSAGE FORM/ STRENGTH: 1 mg/mL oral liquid, 5 mg/mL oral liquid — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Morphine Brand(s): Doloral 1, Doloral 5 (TEMPORARY BENEFIT) DOSAGE FORM/ STRENGTH: 1 mg/mL oral liquid, 5 mg/mL oral liquid For use in a palliative patient requiring oral liquid morphine. Doloral oral liquid products are interim/temporary listing authorized by the Executive Officer as oral liquid morphine products on the formulary were withdrawn from the market by the manufacturer. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 313, corpus 2025-01-01; name match only, not an eligibility decision

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

MS Contin · DIN 02014327 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Marketed since 1993-12-31 · brand MS CONTIN · ATC N02AA01 MORPHINE · form Tablet (extended-release) · route Oral · ingredients MORPHINE SULFATE 200 MG · company Purdue pharma · schedule Narcotics (cdsa i)

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02014327). DIN 02014327: MS Contin Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808057; group id 408; item number 1004; lccId None; manufacturer id PFP Source form: SR Tab; strength: 200mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $7.6274; ministry $4.5738 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02014327 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14142

Interchangeable products

Sandoz Morphine SR · DIN 02478897 · $4.5738 Teva-Morphine SR · DIN 02302802 · $4.5737

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02014327

Shortage record checked 2026-09-13T08:10:21.292534+00:00